Altimmune Net Worth
Altimmune Net Worth Breakdown | ALT |
Altimmune Net Worth Analysis
Altimmune's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Altimmune's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Altimmune's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Altimmune's net worth analysis. One common approach is to calculate Altimmune's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Altimmune's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Altimmune's net worth. This approach calculates the present value of Altimmune's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Altimmune's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Altimmune's net worth. This involves comparing Altimmune's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Altimmune's net worth relative to its peers.
Enterprise Value |
|
To determine if Altimmune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Altimmune's net worth research are outlined below:
| Altimmune had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 426 K. Reported Net Loss for the year was (88.45 M) with loss before taxes, overhead, and interest of (70.52 M). | |
| Altimmune has about 184.76 M in cash with (75.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Altimmune has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Altimmune Gains on Nasdaq Biotechnology Index Inclusion |
Altimmune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Altimmune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Altimmune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Altimmune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Altimmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altimmune backward and forwards among themselves. Altimmune's institutional investor refers to the entity that pools money to purchase Altimmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 758 K | Capital Fund Management Sa | 2024-09-30 | 726.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 646.4 K | Northern Trust Corp | 2024-09-30 | 630 K | Schroder Investment Management Group | 2024-09-30 | 473.9 K | Two Sigma Investments Llc | 2024-09-30 | 454.3 K | Citadel Advisors Llc | 2024-09-30 | 427.6 K | Gsa Capital Partners Llp | 2024-09-30 | 339.6 K | Imc-chicago, Llc | 2024-09-30 | 334.6 K | Blackrock Inc | 2024-06-30 | 5.3 M | Vanguard Group Inc | 2024-09-30 | 5 M |
Follow Altimmune's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 586.78 M.Market Cap |
|
Project Altimmune's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
When accessing Altimmune's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Altimmune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Altimmune's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Altimmune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Altimmune. Check Altimmune's Beneish M Score to see the likelihood of Altimmune's management manipulating its earnings.
Evaluate Altimmune's management efficiency
Altimmune has Return on Asset of (0.3956) % which means that on every $100 spent on assets, it lost $0.3956. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7296) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.51 in 2024. Total Current Liabilities is likely to gain to about 21.2 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 221.2 M in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.65 | 3.46 | |
| Tangible Book Value Per Share | 3.65 | 3.46 | |
| Enterprise Value Over EBITDA | (5.28) | (5.02) | |
| Price Book Value Ratio | 3.09 | 3.24 | |
| Enterprise Value Multiple | (5.28) | (5.02) | |
| Price Fair Value | 3.09 | 3.24 | |
| Enterprise Value | 464.6 M | 487.8 M |
The decision-making processes within Altimmune are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 8.7 K | Revenue 52 K | Quarterly Revenue Growth (0.99) | Revenue Per Share 0.001 | Return On Equity (0.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schafer Klaus over three months ago Acquisition by Schafer Klaus of 26100 shares of Altimmune at 2.5 subject to Rule 16b-3 | ||
Harris Matthew Scott over six months ago Acquisition by Harris Matthew Scott of 58400 shares of Altimmune subject to Rule 16b-3 | ||
Roberts M Scot over six months ago Acquisition by Roberts M Scot of 1436 shares of Altimmune at 10.2085 subject to Rule 16b-3 |
Altimmune Corporate Filings
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 30th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 1st of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Altimmune Earnings per Share Projection vs Actual
Altimmune Corporate Management
| Scot Roberts | Chief Scientific Officer | Profile | |
| Tony BS | Vice Management | Profile | |
| Richard MBA | Chief Officer | Profile | |
| Kent BSEE | Co Controller | Profile | |
| Andrew MS | Corporate Controller | Profile | |
| Bertrand Georges | Chief Officer | Profile |
Already Invested in Altimmune?
The danger of trading Altimmune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Altimmune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Altimmune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Altimmune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.